|
Market Closed -
Nasdaq
16:00:00 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 438.34 USD | -0.14% |
|
+2.87% | +33.92% |
| 10-21 | Barclays Adjusts Price Target on Amgen to $400 From $380 | MT |
| 10-21 | Positive Results for an AstraZeneca and Amgen Product |  |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 126,718 | 140,139 | 154,142 | 140,103 | 176,250 | 236,981 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 34.46% | - | - |
| Enterprise Value (EV) 1 | 151,990 | 169,779 | 207,811 | 188,229 | 221,725 | 278,337 | 272,284 | 267,412 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 25.53% | -2.17% | -1.79% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 27.8x | 24.8x | 23.8x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 21.2x | 17.2x | 13.8x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 2.6x | 2.1x | 5.53x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 6.08x | 5.87x | 5.67x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 7.14x | 6.75x | 6.4x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 12.8x | 12.2x | 12x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 16.4x | 15.3x | 14.5x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 25x | 18.3x | 17.1x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 3.99% | 5.47% | 5.84% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.12 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.3% | 2.43% | 2.54% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 15.75 | 17.64 | 18.4 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 64.1% | 60.4% | 60.4% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 38,967 | 40,352 | 41,806 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,765 | 22,232 | 22,226 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 16,949 | 17,755 | 18,503 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 8,546 | 9,420 | 9,979 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 41,357 | 35,304 | 30,432 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 438.34 | 438.34 | 438.34 |
| Nbr of stocks (in thousands) | 563,266 | 533,579 | 535,178 | 537,533 | 538,481 | 540,632 | - | - |
| Announcement Date | 2/7/22 | 1/31/23 | 2/6/24 | 2/4/25 | 2/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.87x | 7.15x | 12.8x | 2.3% | 237B | |
| 36.99x | 13.22x | 28x | 0.53% | 1,144B | |
| 37.96x | 6.39x | 17.99x | 2.06% | 625B | |
| 36.9x | 8.47x | 17.49x | 2.38% | 511B | |
| 21.13x | 5.1x | 12.68x | 2.57% | 377B | |
| 108.1x | 6.04x | 25.89x | 2.3% | 366B | |
| 21.5x | 5.61x | 13.79x | 2.85% | 291B | |
| 22.06x | 4.46x | 12.76x | 1.98% | 262B | |
| -45.73x | 7.01x | 27.13x | 2.11% | 194B | |
| 11.42x | 4.2x | 8.55x | 4.4% | 174B | |
| Average | 27.82x | 6.76x | 17.71x | 2.35% | 418.16B | |
| Weighted average by Cap. | 34.48x | 8.17x | 20.00x | 1.91% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
